Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma NetworkEva Hoster, Andreas Rosenwald, Françoise Berger, et al.Nature|August 2, 2019
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 9, 2019
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationDonal McLornan, Richard Szydlo, Linda Koster, et al.Nature|July 19, 2019
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 2, 2019
Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell TransplantationNico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.Leukemia|August 30, 2019
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysisStefan Knop, Monika Engelhardt, Peter Liebisch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.Pageof 21